

# Certificate of Analysis for NR-52154

### Acinetobacter baumannii, Strain MRSN 1174

## Catalog No. NR-52154

This reagent is the tangible property of the U.S. Government.

### **Product Description:**

Acinetobacter baumannii (A. baumannii), strain MRSN 1174 was isolated in 2006 from a human blood sample in the USA as part of a global surveillance program. A. baumannii, strain MRSN 1174 was deposited as multi-locus sequence type (MLST) ST 2, sensitive to colistin and ampicillin/sulbactam, intermediately resistant to tetracycline and resistant to amikacin, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin and trimethoprim/sulfamethoxazole. NR-52154 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70038530 Manufacturing Date: 26AUG2020

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <a href="mailto:Contact@BEIResources.org">Contact@BEIResources.org</a>. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C¹ 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Non-motile
VITEK® MS (MALDI-TOF)	A. baumannii	A. baumannii (99.9%)
Antibiotic Susceptibility Profile <sup>2,3</sup>		
Amikacin	Resistant	Intermediate (24 µg/mL) <sup>4</sup>
Ampicillin/sulbactam	Sensitive	Resistant (96 µg/mL) <sup>5</sup>
Cefepime	Resistant	Resistant (32 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Resistant	Resistant (12 to 16 µg/mL)
Levofloxacin	Resistant	Resistant (4 to 8 µg/mL)
Meropenem	Resistant	Resistant (> 32 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (> 4 µg/mL)
Tobramycin	Resistant	Sensitive (4 µg/mL) <sup>6</sup>
Tetracycline	Intermediate	Resistant (≥ 256 µg/mL) <sup>7</sup>
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (1480 base pairs)	≥ 99% sequence identity to  A. baumannii, strain MRSN 1174 (GenBank: VHHF01000099.1)	99.9% sequence identity to  A. baumannii, strain MRSN 1174 (GenBank: VHHF01000099.1)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898




# **Certificate of Analysis for NR-52154**

TEST	SPECIFICATIONS	RESULTS
Purity 8 days at 37°C in an aerobic atmosphere with and without 5% CO <sub>2</sub> on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

<sup>&</sup>lt;sup>1</sup>Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus and A. pittii*, which do not grow at 44°C.

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

21 JAN 2022

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

<sup>&</sup>lt;sup>3</sup>Antibiotic susceptibility was tested using a combination of VITEK®2 GN82, Sensititre GNX2F AST and E-test strips.

<sup>&</sup>lt;sup>4</sup>A. baumannii, strain MRSN 1174 was deposited as being resistant to amikacin. Repeated antibiotic susceptibility testing determined that for strain MRSN 1174, the amikacin MIC is 24 µg per mL, which is interpreted as intermediately resistant. Testing was performed in duplicate.

<sup>&</sup>lt;sup>5</sup>A. baumannii strain MRSN 1174 was deposited as being sensitive to ampicillin/sulbactam. Repeated antibiotic susceptibility testing determined that for strain MRSN 1174, the ampicillin/sulbactam MIC is 96 µg per mL, which is interpreted as resistant. Testing was performed in duplicate.

<sup>&</sup>lt;sup>6</sup>A. baumannii, strain MRSN 1174 was deposited as being resistant to tobramycin. Repeated antibiotic susceptibility testing determined that for strain MRSN 1174, the tobramycin MIC is 4 μg per mL, which is interpreted as sensitive. Testing was performed in duplicate.

<sup>7</sup>A. baumannii, strain MRSN 1174 was deposited as being intermediately resistant to tetracycline. Repeated antibiotic susceptibility testing determined that for strain MRSN 1174, the tetracycline MIC is ≥ 256 µg per mL, which is interpreted as resistant. Testing was performed in duplicate.